Form 4: United Therapeutics Director Richard Giltner Reports Acquisition of Restricted Stock Units

Director Richard Giltner reports acquisition of 1,190 restricted stock units in United Therapeutics Corp.

Summary

• On July 25, 2024, Richard Giltner, a director of United Therapeutics Corporation, acquired 1,190 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of United Therapeutics Corporation common stock upon vesting.
• The RSUs were granted as an annual non-employee director award and vest on the one-year anniversary of the grant date, July 25, 2025.
• Following the transaction, Giltner directly owns 1,190 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs in one year suggests an expectation of continued service by the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.

Stakeholder Impact

• The acquisition of RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates